GB2110090A - Parasiticidal compositions - Google Patents

Parasiticidal compositions Download PDF

Info

Publication number
GB2110090A
GB2110090A GB08233717A GB8233717A GB2110090A GB 2110090 A GB2110090 A GB 2110090A GB 08233717 A GB08233717 A GB 08233717A GB 8233717 A GB8233717 A GB 8233717A GB 2110090 A GB2110090 A GB 2110090A
Authority
GB
United Kingdom
Prior art keywords
pour
composition according
levamisole
solvent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08233717A
Other versions
GB2110090B (en
Inventor
David Alwyn Charles Evans
David Ernest Pryor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orica Ltd
Original Assignee
ICI Australia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICI Australia Ltd filed Critical ICI Australia Ltd
Publication of GB2110090A publication Critical patent/GB2110090A/en
Application granted granted Critical
Publication of GB2110090B publication Critical patent/GB2110090B/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017Non-human animal skin, e.g. pour-on, spot-on

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition for topical application to animals to control endoparasites comprising a mixture of levamisole or tetramisole free base in a carrier comprising particular combinations of an alcohol solvent with an ester co-solvent.

Description

SPECIFICATION Parasiticidal compositions This invention relates to compositions for topical application of chemicals to animals for the control of parasites. In particular it relates to compositions comprising levamisole free base for the control of endoparasites.
Internal applications of parasiticides for the control of endoparasites is well known and usually takes the form of injecting or drenching animals with suitable formulations of the parasiticides.
Recently attempts have been made to develop pour-on formulations, that is, formulations that are fully effective against parasites when a suitable amount of the formulation is applied to a particular area of the animal's surface, typically along the spinal region. A pour-on approach has inherent advantages over the other techniques in removing the need to restrain animals and to maintain sterile formulations. In addition trained personnel are not needed. Formulations prepared for pour-on application of endoparasiticides have so far suffered from a number of disadvantages. The range of parasiticides which are effective in this technique are limited and the prior art compositions have associated tissue reactions caused by the solvent systems used for preparing these compositions.These tissue reactions lead to considerable discomfort for the treated animals and in addition lead to severe damage to the hides and skins of the animals with consequent economic loss to the grazier. This is a particular problem with sheep in Australia where the major sheep breed in the Merino or Merino-cross, since this breed has been found to be very sensitive even to those solvent systems which have been tolerated to some degree by other breeds.
It is an object of the present invention to provide effective and non-toxic solvent systems that are tolerated by animals with a wide range of type and degree of sensitivity.
In the case of pour-on application to sheep, immediately after shearing is potentially a good time to treat sheep for parasite control by topical application since the sheep are already mustered and the wool is relatively short. However the wool cover is still a significant barrier to the topically applied compositions particularly in the case of Merinos because the individual fibres are fine and closely packed. In addition there is a layer of wool grease covering the skin which provides a further barrier to penetration of the medication. This layer of wool grease can reach a very high level in Merinos. It is a further object of our invention to provide compositions which are effective in penetrating these wool and wool grease barriers while maintaining the freedom from adverse skin and tissue reactions.
Degreasing solvents such as for example, paraffins, isoparaffins, cycloparaffins and aromatics such as the xylene, are well known. However these solvents, which effectively penetrate the wool grease cover, produce severe tissue reactions such as pain, swelling, dryness and cracking of the skin. This in turn leads to wool loss and permanent hide damage.
Other solvents, such as alcohols and alcohol ethoxylates, do not produce tissue reactions but are relatively ineffective at penetrating the wool or wool grease cover.
We have now found certain compositions which are effective for the topical application to animals of the endoparasiticides, tetramisole and levamisole, and which are free from adverse tissue reaction even when applied to sensitive breeds of animals. A further advantage of these compositions is that organo-metallic materials may be readily incorporated to counteract specific mineral deficiencies in the animals.
Accordingly we provide compositions for topical application to animals for the control of endoparasites which compositions comprise levamisole or tetramisole in its free base form in a carrier comprising a first solvent selected from the group consisting of C3 to C4 alcohols alkoxylated with from one to three moles of ethylene oxide per mole of alcohol, and C, to C4 alcohols alkoxylated with from one to three moles of propylene oxide per mole of alcohol and mixtures thereof; and a co-solvent selected from di(C, to C6 alkyl) esters of C2 to C6 dicarboxylic acids, di(C, to C6 alkyl) esters of C2 to C6 dihydric alcohols, and C2 to C8 carboxylic esters of alcohol alkoxylates prepared by reacting one mole of a C3 to C6 alcohol with from one to three moles of an alkylene oxide selected from ethylene oxide and propylene oxide, and mixtures thereof.
The preferred C2 to C8 dicarboxylic acids are adipic acid and sebacic acid, and the preferred esters of these acids are dimethyl adipate, diethyl adipate, dimethyl sebacate, and diethyl sebacate. The preferred C2 to C6 dihydric alcohols are ethylene glycol, propylene glycol, diethylene glycol, and triethylene glycol.
Tetramisole is the common name for the hydrochloride salt of the anthelmintic d1-2,3,5,6- tetrnhydrnimidazo2, 1-b]thiazole. Levamisole is the common name for the laevo-rotatory optical isomer of tetramisole. For the compositions of the present invention these hydrochloride salts are unsuitable being of low solubility in the first solvent and essentially insoluble in the co-solvent.
Tetramisole and levamisole are readily converted to the respective free base forms for the compositions of the present invention by conventional methods of basifying the salts. The preferred compound is the free base of levamisole.
The preferred first solvents are 2-propoxyethanol, 2-butoxyethanol, 1-methyl-2-propanol and 1-ethoxy-2-propanol, and mixtures thereof. The preferred co-solvents are ethylene glycol diacetate, 2-propoxyethyl acetate, 2-butoxyethyl acetate and 1 -methoxypropyl-2 acetate, and mixtures thereof. The most preferred carrier comprises 2-butoxyethanol and ethylene glycol diacetate.
These particular carriers provide rapid wetting of the wool or hair of the animal permitting movement to the skin level with minimal run-off and loss of formulation, and have the required solubility for the endoparasites.
Preferably the weight/weight ratio of the first solvent to the co-solvent is in the range from 9:1 to 1:1.
The concentration of the levamisole free base in the compositions of our invention is in the range from 1.0 to 25% weight/volume. The particular concentration can be readily chosen by those skilled in the art so that when a selected quantity of the solution of the endoparasiticide is applied topically to the animal then the parasiticide will be present in an effective amount to control the particular parasitic infestations in the animal.
For animals infested with parasitic gastro intestinal and pulmonary nematodes such as Haemonchus spp., Ostertagia spp., Trichostrongylus spp., Nematodirus spp., Oesophagostomum spp., Chabertia spp., and Dictyocaulus spp. a typical effective amount of levamisole free base is approximately 10 mg/kg of animal body weight by topical application.
The preferred compositions comprises from 5 to 20% of levamisole free base in a preferred carrier such that the levamisole free base is close to the saturation point in that carrier.
The species of parasites controlled by levamisole have been well-documented in the prior art.
It is a particular feature of our compositions that the levamisole is fully effective in topical applications in the compositions of our invention at the same dose rates that are employed by conventional methods of applications such as oral drenching and injection.
Thus, for example, a composition containing 5% w/v of levamisole applied at the rate of 0.2 ml/kg of animal bodyweight gives effective control of helminths.
While the compositions are particularly effective for control of endoparasites in cattle and sheep they may also be used for pigs and domestic animals such as dogs and cats.
The compositions may additionally contain other ingredients such as, for example, preservatives and stabilizers. A particularly useful stabilizer is an antioxidant such as for example 4-butyl2,5-dimethylphenol. Other antioxidants known to those skilled in the art may be used and the selected antioxidant or mixture of antioxidants is typically added to provide a concentration in the range of from 0.1 to 1.0% w/v, preferably 0.5 to 1.0% w/v, in the final composition.
In a further embodiment of our invention we provide compositions which additionally comprise a non-fast dye so that animals treated with the pour-on compositions may be readilv recognized and thus unnecessary and undesirable duplicate treatment may be avoided. Suitable non-fast dyes soluble in the compositions will be readily selected by those skilled in the art so that the dyed area of skin or wool will fade in sunlight within a suitable period of exposure and without deleterious effect on the skin or wool. A particularly useful dye is rhodamine which is typically used in an amount to give a concentration range of from 0.01 to 0.05% w/v in the final composition.
In a further embodiment of our invention we provide a process of treating animals which process comprises applying to the surface of the animals the composition of our invention comprising levamisole or tetramisole in the free base form in a first solvent as hereinbefore defined and a co-solvent as hereinbefore defined.
The compositions of our invention are applied in a iine along the back of the animal from the withers to the rump. The compositions spontaneously "wet" and penetrate the wool or hair and migrate rapidly down to the skin level. The compositions may be applied by brushing or rollingon but more conveniently are simply poured on to the back of the animal.
In a further preferred embodiment of our invention the compositions additionally contain one or more carboxylic acids selected from the group consisting of C1 to Cs alkanoic acids. The molar ratio of alkanoic acid to levamisole free base should not exceed 1.1 and most preferably the alkanoic acid and levamisole free base are in substantially equimolar proportions. The addition of the alkanoic acid to the composition increases the measured blood levels of levamisole in the treated animals. Smaller proportions of alkanoic acid give a correspondingly smaller increase in the blood levels and the preferred molar ratio of alkanoic acid to levamisole free base is in the range of 0.5 to 1.0. The preferred alkanoic acids are the C1 to C4 acids, in particular acetic and propionic acid. Higher molecular weight acids, for example stearic acid, can be used but provide less blood level enhancement than the C1 to C8 alkanoic acids.
This invention is now illustrated by but not limited to the following examples in which all parts and percentages are by weight unless otherwise specified.
Example I A formulation is prepared with the following composition: Rhodamine 0.1% w/v Levamisole free base 10% w/v Ethylene glycol diacetate 25% v/v 2-Butoxyethanol to 100 vols Example 2 A formulation is prepared with the following composition: Rhodamine 0.1% w/v Levamisole free base 10% w/v Ethylene glycol diacetate 25% w/v 1 -Methyl-2-propanol to 100 vols Example 3 A formulation is prepared with the composition of Example 2 except that the 1-methoxy-2propanol is replaced with 1-ethoxy-2-propanol.
Example 4 A formulation is prepared with the following composition: Rhodamine 0.1 % w/v Levamisole 10% w/v Ethylene glycol diacetate 20% w/v Propionic acid 3.6% w/v 2-Butoxyethanol to 100 vols Example 5 A formulation is prepared with the composition of Example 4 except that the 2-butoxyethanol is replaced by 1-methoxy-2-propanol.
Example 6 A formulation is prepared with the composition of Example 4 except that the propionic acid is replaced with an equimolar amount of octanoic acid.
Example 7 A formulation is prepared with the composition of Example 4 except that the concentration of propionic is 1.8% w/v.
Example 8 Cattle were treated with the formulation of Example 1 by pour-on application along the spine.
The applied dose was 1 ml/kg bodyweight to provide an effective dose rate of 10 mg/kg of levamisole. Control animals were treated subcutaneously with a levamisole injectable formulation at a dose rate of 6 mg/kg bodyweight.
Blood samples were drawn from the animals at regular time intervals and heparinized. The plasma obtained by centrifugation was then analyzed for levamisole by a procedure involving clean-up on "Sep-Pak" C16 cartridges ("Sep-Pak" is a registered trade mark of Waters Associates) followed by a final determination by high performance liquid chromatography. The results are given in Table 1 and indicate that blood levels of 0.3 ppm and higher are rapidly reached and then maintained over a five-hour period. This level is known by those skilled in the art to give effective control of helminth parasites.
TABLE 1 Levamisole conc (ppm) in plasma after treatment Animal Treatment number Hours: 1 2 3 5 7 Injectable formulation 1 1.1 0.6 0.5 0.3 0.2 Injectable formulation 2 1.5 1.2 0.9 0.5 0.2 Pour-on formultion 3 0.6 0.6 0.5 0.3 0.2 Pour-on formulation 4 0.4 0.5 0.4 0.3 0.3 Example 9 The procedure of Example 8 was followed with the pour-on formulation of the following composition: Levamisole free base 10% w/v Ethylene glycol diacetate 20% w/v 2-Butoxyethanol to 100 vols The results for the treated animals are shown in Table 2.
Example 10 The procedure of Example 8 was followed with a pour-on formulation of the following composition: Levamisol free base 10% w/v Acetic acid 2.5% w/v Ethyleneglycol diacetate 20% w/v 2-Butoxyethanol to 100 vols The results for the treated animals are shown in Table 2.
Example ii The procedure of Example 8 was followed with a pour-on formulation of the composition of Example 4. The results are shown in Table 2.
TABLE 2 Levamisole conc (ppm) in plasma after treatment Example Hours: 1 2 3 4 9 Animal No 1 0.22 0.33 0.39 0.44 No No 2 0.16 0.31 0.56 0.53 10 Animal No 1 0.69 1.61 1.21 1.07 ,, No 2 0.14 0.31 0.87 0.82 11 0.36 0.77 0.81 1.14 Comparative Example 1 A formulation was prepared with the composition of Example 1 except that the ethylene glycol diacetate was omitted. When this formulation was applied to three sheep by the procedure of Example 8 at an application dose of 4 ml tissue hardening on the animal was noted after six days.
Comparative Example 2 A formulation was prepared with the composition of Example 4 except that the ethylene glycol diacetate was omitted. When this formulation was applied to three sheep by the procedure of Example 8 at an application dose of 4 ml, the tissue at the site of application became dry and hard after six days.
Comparative Example 3 A formulation was prepared with the composition of Example 7 except that the ethylene glycol diacetate was omitted. The formulation was applied to three sheep by the procedure of Example 8 at an application dose of 4 ml. After six days the tissue at the site of application was dry and cracking had occurred.

Claims (12)

1. A pour-on composition for controlling or eradicating endoparasite infestations in animals comprising an endoparasiticidal amount of tetramisole free base or an optical isomer thereof in a carrier comprising a first solvent selected from the group consisting of C3 to C4 alcohols alkoxylated with from one to three moles of ethylene oxide per mole of alcohol, and C, to C4 alcohols alkoxylated with from one to three moles of propylene oxide per mole of alcohol and mixtures thereof, and a co-solvent selected from di-(C, to C6 alkyl)esters of C2 to C6 dicarboxylic acids, di(C, to C6 alkyl esters of C2 to C6 dihydric alcohols, and C2 to C6 carboxylate esters of alcohol alkoxylates prepared by reacting one mole of a C3 to C6 alcohol with from one to three moles of an alkylene oxide selected from ethylene oxide and propylene oxide, and mixtures thereof.
2. A pour-on composition according to claim 1 wherein the isomer of tetramisole is levamisole.
3. A pour-on composition according to claim 2 wherein the animals comprise cattle or sheep.
4. A pour-on composition according to claim 3 wherein the C2 to C6 dicarboxylic acids are adipic acid and sebacic acid and the C2 to C6 dihydric alcohols are ethylene glycol, propylene glycol, diethylene glycol and triethylene glycol.
5. A pour-on composition according to claim 4 wherein the concentration of levamisole free base is in the range of from 1.0 to 25% w/v.
6. A pour-on composition according to claim 5 wherein the carrier forms 70 to 98% w/v of the composition and the weight/weight ratio of the first solvent to the co-solvent is in the range from 9:1 to 1:1.
7. A pour-on composition according to any one of claims 4 to 6 wherein the first solvent is selected from the group consisting of 2-propoxyethanol, 2-butoxyethanol, 1-methoxy-2-propanol and 1-ethoxy-2-propanol, and mixtures thereof.
8. A pour-on composition according to any one of claims 4 to 6 wherein the co-solvent is selected from the group consisting of ethylene glycol diacetate, 2-propoxyethyl acetate, 2 butoxyethyl acetate and 1-methoxypropyl-2-acetate, and mixtures thereof.
9. A pour-on composition according to claim 5 or claim 6 wherein the carrier comprises 2 butoxyethanol and ethylene glycol diacetate.
1 0. A pour-on composition according to any one of claims 2 to 9 wherein the carrier additionally comprises a C, to C6 alkanoic acid such that the molar ration of alkanoic acid to levamisole is in the range from 0.5 to 1.1.
11. A pour-on composition according to claim 10 wherein the levamisole and C, to C6 alkanoic acid are in substantially equimolar proportions.
1 2. A method of controlling or eradicating endoparasite infestations from animals which method comprises applying to a portion of said animal a composition as claimed in any one of claims 1 to
12.
1 3. Pour-on compositions substantially as described herein and with reference to the examples.
GB08233717A 1981-11-27 1982-11-26 Parasiticidal compositions Expired GB2110090B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPF173181 1981-11-27

Publications (2)

Publication Number Publication Date
GB2110090A true GB2110090A (en) 1983-06-15
GB2110090B GB2110090B (en) 1985-04-17

Family

ID=3769280

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08233717A Expired GB2110090B (en) 1981-11-27 1982-11-26 Parasiticidal compositions

Country Status (7)

Country Link
DE (1) DE3244116A1 (en)
ES (1) ES8500713A1 (en)
FR (1) FR2517205B1 (en)
GB (1) GB2110090B (en)
IE (1) IE54306B1 (en)
NZ (1) NZ202526A (en)
ZA (1) ZA828525B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136033A2 (en) * 1983-08-22 1985-04-03 Ici Australia Limited Pour-on formulation for the control of parasites
EP0137627A2 (en) * 1983-08-12 1985-04-17 Pitman-Moore Australia Limited Pour-on formulation for the control of parasites

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE38848B1 (en) * 1973-02-23 1978-06-07 Fisons Ltd Anthelmintic method and composition
NL180633C (en) * 1973-06-22 1900-01-01 Bayer Ag PROCESS FOR PREPARING AN ANTHELMINTIC EFFECTIVE VETERINARY Pour-on Preparation.
DE2614841A1 (en) * 1976-04-06 1977-10-20 Bayer Ag NEW POUR-ON FORMULATIONS FROM ANTHELMINTIKA
US4278684A (en) * 1980-06-17 1981-07-14 Janssen Pharmaceutica N.V. Non-toxic anthelminthic pour-on composition
GB2095107A (en) * 1981-03-24 1982-09-29 Janssen Pharmaceutica Nv Tetramisole-or levamisole pour-on compositions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0137627A2 (en) * 1983-08-12 1985-04-17 Pitman-Moore Australia Limited Pour-on formulation for the control of parasites
EP0137627A3 (en) * 1983-08-12 1986-03-12 Ici Australia Limited Pour-on formulation for the control of parasites
EP0136033A2 (en) * 1983-08-22 1985-04-03 Ici Australia Limited Pour-on formulation for the control of parasites
EP0136033A3 (en) * 1983-08-22 1986-03-12 Ici Australia Limited Pour-on formulation for the control of parasites

Also Published As

Publication number Publication date
IE54306B1 (en) 1989-08-16
DE3244116A1 (en) 1983-07-07
DE3244116C2 (en) 1993-02-18
IE822800L (en) 1983-05-27
GB2110090B (en) 1985-04-17
FR2517205B1 (en) 1987-06-26
ES517710A0 (en) 1984-11-01
FR2517205A1 (en) 1983-06-03
ES8500713A1 (en) 1984-11-01
NZ202526A (en) 1985-10-11
ZA828525B (en) 1983-09-28

Similar Documents

Publication Publication Date Title
EP0137627B1 (en) Pour-on formulation for the control of parasites
OA11678A (en) Antiparasitic formulations.
EP1136081B1 (en) Sustained-release compositions for the parenteral administration of macrolides
KR0169559B1 (en) Pour-on formulations containing polymeric material, glycols and glycerides
CA2594981C (en) Anthelmintic composition
GB2110091A (en) Parasiticidal compositions
US4018932A (en) Anthelmintic pour-on formulations for topical use on domestic and farm animals
EP0136033A2 (en) Pour-on formulation for the control of parasites
KR870001791B1 (en) Non-irritating tetramisole or levamisole pour-on composition
GB2110090A (en) Parasiticidal compositions
NZ202525A (en) Ectoparasiticidal compositions containing pyrethroid
NO175882B (en) Process for the preparation of parenteral, antiparasitic formulations of the compound 25-cyclohexyl avermectin B1
US4618618A (en) Compounds and compositions
CA2014157C (en) Antiparasitic formulation containing 25-cyclohexyl-avermectin b1
RU2278661C2 (en) Anti-parasitic preparation
KR20040009184A (en) Ivermectin composition for injection and method for preparing the same

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20021125